The FDA has formed a panel for an upcoming review of peptides that consists primarily of health professionals who prescribe, produce, or promote such compounds. Multiple unverified claims describe the meeting details, prior panel makeup, and market context for peptides. Analyses from progressive, conservative, libertarian, and critical viewpoints interpret the panel composition differently.